An in vitro test system for compounds that modulate human inflammatory macrophage polarization

Area of Science:

• Immunology and Pharmacology
• Cell Biology
• Drug Discovery

Background:

• Macrophages polarize into M1 (pro-inflammatory) and M2 (anti-inflammatory) phenotypes.
• Imbalance in M1-M2 polarization is linked to inflammatory diseases.
• Targeting macrophage polarization mechanisms may offer new therapeutic strategies.

Purpose of the Study:

• To profile compounds for their effects on macrophage polarization.
• To establish a reliable test system for identifying modulators of macrophage plasticity.
• To identify potential drug candidates for treating chronic inflammatory diseases.

Main Methods:

• Peripheral blood monocyte-derived macrophages were used.
• Macrophage polarization was induced using lipopolysaccharide (LPS) + interferon-γ (IFNγ) for M1 and interleukin-4 (IL-4) for M2.
• A panel of M1 and M2 markers (e.g., IL1β, TNFα, CCR7, CD80, CCL22, CD200R, MRC1) was used to assess drug effects.
• Six compounds were tested for their ability to modulate M1 or M2 polarization.

Main Results:

• Azithromycin, tofacitinib, hydroxychloroquine, and pioglitazone demonstrated an anti-inflammatory profile, downregulating M1 markers and upregulating M2 markers.
• Lovastatin showed mixed effects, downregulating M1 markers but enhancing the M1 phenotype in pre-polarized cells.
• Methotrexate did not significantly modulate macrophage polarization.
• The study established a functional test system for evaluating drug effects on macrophage polarization.

Conclusions:

• A novel test system for macrophage polarization modulation was successfully established.
• Several compounds, including azithromycin and hydroxychloroquine, exhibit potential as anti-inflammatory agents by shifting macrophage phenotype.
• Compounds that reduce inflammatory markers (IL-1β, TNFα, CD80) and increase Treg recruitment chemokine (CCL22) are promising for chronic inflammatory disease treatment.